Alexion Pharmaceuticals (ALXN) : Lebenthal Holdingsllc scooped up 158 additional shares in Alexion Pharmaceuticals during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Apr 20, 2016. The investment management firm now holds a total of 32,953 shares of Alexion Pharmaceuticals which is valued at $5,242,822.Alexion Pharmaceuticals makes up approximately 0.90% of Lebenthal Holdingsllc’s portfolio.
Alexion Pharmaceuticals closed down -2.28 points or -1.41% at $159.1 with 12,16,634 shares getting traded on Friday. Post opening the session at $161.04, the shares hit an intraday low of $157.36 and an intraday high of $162 and the price fluctuated in this range throughout the day.Shares ended Friday session in Red.
Other Hedge Funds, Including , Winslow Evans Crocker reduced its stake in ALXN by selling 1 shares or 0.65% in the most recent quarter. The Hedge Fund company now holds 153 shares of ALXN which is valued at $24,342. Alexion Pharmaceuticals makes up approx 0.01% of Winslow Evans Crocker’s portfolio.Gulf International Bank (uk) Ltd boosted its stake in ALXN in the latest quarter, The investment management firm added 790 additional shares and now holds a total of 67,147 shares of Alexion Pharmaceuticals which is valued at $10,683,088. Alexion Pharmaceuticals makes up approx 0.18% of Gulf International Bank (uk) Ltd’s portfolio. Monroe Bank Trustmi added ALXN to its portfolio by purchasing 24 company shares during the most recent quarter which is valued at $3,674.Creative Planning boosted its stake in ALXN in the latest quarter, The investment management firm added 6,424 additional shares and now holds a total of 21,652 shares of Alexion Pharmaceuticals which is valued at $3,201,898. Alexion Pharmaceuticals makes up approx 0.03% of Creative Planning’s portfolio.
On the company’s financial health, Alexion Pharmaceuticals reported $1.13 EPS for the quarter, beating the analyst consensus estimate by $ 0.03 according to the earnings call on Feb 3, 2016. Analyst had a consensus of $1.10. The company had revenue of $700.90 million for the quarter, compared to analysts expectations of $702.36 million. The company’s revenue was up 16.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.30 EPS.
Many Wall Street Analysts have commented on Alexion Pharmaceuticals. Shares were Downgraded by Robert W. Baird on Mar 8, 2016 to ” Neutral” and Lowered the Price Target to $ 170 from a previous price target of $221 .Citigroup Initiated Alexion Pharmaceuticals on Feb 25, 2016 to “Buy”, Price Target of the shares are set at $165.Shares were Reiterated by UBS on Feb 4, 2016 to “Buy” and Lowered the Price Target to $ 200 from a previous price target of $222 .
Alexion Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of life-transforming therapeutic products. As of June 23 2015 the Company had eight product candidates in clinical trials for 11 indications. The Company’s product pipeline includes complement inhibitor portfolio metabolic rare disease portfolio and preclinical candidates. Its complement inhibitor portfolio includes Soliris ALXN1007 ALXN1210 and ALXN5500. Its metabolic rare disease portfolio includes Strensiq Kanuma ALXN1101 and SBC-103. The Company’s preclinical candidates include mRNA Therapies SBC-105 and other complement inhibitors. Its Soliris is approved for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS) two life-threatening ultra-rare disorders.